Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...

In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $63.00. Discover ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported EPS is $-1.11 EPS, expectations were $-0.33. Operator: Good day, everyone, and welcome to Arcturus Therapeutics Fourth ...

The Japanese drugs giant Takeda and the US biotech Arcturus Therapeutics have joined the hunt for therapies for the COVID-19 coronavirus. As the infection and death count continues to rise across ...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...